-
1 Comment
Ocugen, Inc is currently in a long term uptrend where the price is trading 42.1% above its 200 day moving average.
From a valuation standpoint, the stock is 1237.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 17564.7.
Ocugen, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 130.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 48.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Ocugen, Inc gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | US67577C1053 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 3.79 |
|---|---|
| Market Cap | 186M |
| PE Ratio | None |
| Target Price | 7.9 |
| Dividend Yield | None |
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2H51.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
